FCGR3A and COVID-19: In addition to COVID-19, we recently discovered an expansion of the CD16+ T cell population in BALF from patients with Pneumocystis jirovecii pneumonia (PCP) compared to cytotoxic drug-induced ILD and immune-checkpoint inhibitor-associated ILD [24].